Celltrion, a biopharmaceutical company, has announced plans to enter the CDMO market with a 1.5 trillion won (approximately $1 billion) to construct a 200,000-liter production facility in Korea.

To support the expansion, Celltrion will open R&D centers in India, the US, and Europe, hiring 500 Ph.D.-level researchers, aiming to offer a comprehensive range of CDMO services related to monoclonal antibodies, bispecific antibodies, and ADCs.